NDAINJECTIONINJECTABLE
Approved
Oct 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
14
Data completeness
4/8 — Partial
TRIAMCINOLONE ACETONIDE (triamcinolone acetonide) by Design Pharmaceuticals is corticosteroid hormone receptor agonists [moa]. Approved for diabetic macular edema, acute gout, macular edema and 4 more indications. First approved in 1987.
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Triamcinolone acetonide is a synthetic corticosteroid that works by agonizing glucocorticoid receptors to suppress immune and inflammatory responses. Administered via injection, it treats a broad spectrum of inflammatory and allergic conditions including diabetic macular edema, uveitis, atopic dermatitis, acute gout, and allergic rhinitis. The drug has been on the market since 1987 and remains a foundational therapy across ophthalmology, rheumatology, and dermatology.
LOE Approaching
As a mature product approaching loss of exclusivity, the brand team is likely in optimization and cost-management mode rather than growth expansion.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Indications (7)
Worked on TRIAMCINOLONE ACETONIDE at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.